Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toyota Tsusho to Represent GHL in Japan for Biosimilars Contract Manufacturing Service
June 6, 2011
- Wholesalers Were the Only Losers: Chairman Matsutani of Toho
June 6, 2011
- Eisai, UCL to Collaborate in Neurodegenerative Disease
June 6, 2011
- ASKA Licenses Ulipristal from Laboratoire HRA
June 6, 2011
- Nihon Chouzai to Open More Stores Filling Prescriptions from Wide Range of Med Institutions
June 6, 2011
- Pfizer Japan Signs Comprehensive Agreement with NCC for Clinical Trials of Anticancer Drugs
June 6, 2011
- Kantar Health Highlights Crizotinib
June 6, 2011
- R&I Downgrades Takeda Following Announcement of Acquisition of Nycomed
June 6, 2011
- Nippon Zoki, Teikoku Seiyaku to Codevelop Adhesive Agent for PHN
June 6, 2011
- Daiichi Sankyo Aims for Sales of ¥40 Bil. in China
June 6, 2011
- HPV Vaccine Gardasil Recommended for Approval
June 6, 2011
- ¥45.5 Billion Worth of New-type Flu Vaccines Discarded: Health Minister Hosokawa
June 6, 2011
- Astellas Looking for Partner for Global Development of Darexaban
June 6, 2011
- ASKA's Emergency Pill Priced at ¥10,000/Dose
June 6, 2011
- Teijin Pharma to Collect More Evidence on Efficacy of Feburic for Hyperuricemia
June 6, 2011
- JPA Opposes Drug Price Revision without Revision of Medical, Nursing Fees
June 6, 2011
- Santen Regains Top Spot in Domestic Glaucoma Market
June 6, 2011
- Sitagliptin Approved for Combination Therapy with αGI: MSD, Ono
June 6, 2011
- Seikagaku Preparing to Launch Gel-One in US Despite Patent Dispute
June 6, 2011
- Pfizer Files Simultaneous Application for Crizotinib in the US, Japan
June 6, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…